J Gayoso, R Martino, P Balsalobre… - Therapeutic …, 2011 - tah.sagepub.com Abstract: Background: We herein report the long-term results of an allogeneic reduced-intensity con- ditioning (allo-RIC) protocol used in 21 consecutive patients (16 males, median age 56 years, 71% in complete remission) diagnosed with mantle cell lymphoma (MCL). ... All 2 versions
[PDF] from hematologylibrary.orgMT Cibeira, V Sanchorawala… - …, 2011 - bloodjournal.hematologylibrary.org Page 1. 1 Outcome of AL Amyloidosis after High-dose Melphalan and Autologous Stem Cell ... 3 ABSTRACT Previous studies have suggested that in patients with AL amyloidosis treated with high- dose melphalan and autologous stem-cell transplantation (HDM/SCT), the greatest ... View as HTML
K Kemp, R Morse, K Sanders, J Hows… - Annals of hematology, 2011 - Springer Abstract The adverse effects of melphalan and cyclophos- phamide on hematopoietic stem cells are well-known; however, the effects on the mesenchymal stem cells (MSCs) residing in the bone marrow are less well characterised. Examining the effects of chemotherapeutic agents on ... Cited by 1 - Related articles - All 5 versions
D Telio, J Shepherd, D Forrest, L Zypchen… - Bone Marrow …, 2011 - nature.com Light chain and light and heavy chain deposition disease (LCDD and LHCDD) are plasma cell dyscrasias in which aggregation and deposition of Ig components leads to organ dysfunction. Although similar in principle to light chain (AL) amyloidosis, there are a ... Cited by 1 - All 3 versions
P Kapoor, SV Rajkumar, A Dispenzieri, MA Gertz… - Leukemia, 2011 - nature.com Trials comparing efficacy of melphalan prednisone (MP) with MP plus thalidomide in transplant ineligible, elderly patients with multiple myeloma have provided conflicting evidence. Although there is agreement regarding improved response rates (RRs) and higher toxicity with the ... Cited by 8 - Related articles - All 4 versions
沪公网安备号：31010402006960 （网站）31010405000484 （蝌蝌APP）
安全保密
